You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

azaCITIDine

( ay-za-SYE-ti-deen )
Funding:
New Drug Funding Program
  • Azacitidine - Acute Myeloid Leukemia (AML)
  • Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
  • Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts
... Show more tags
Other Name(s): Vidaza®
Appearance: White, milky suspension for injection

Drug Monograph

Dec 2020
Table of Contents
Eligibility Forms
pdf download Azacitidine - Acute Myeloid Leukemia (AML) pdf download Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS) pdf download Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30 Percent Blasts

Patient Info Sheet

Apr 2016

What it is used for

  • For treating certain types of blood disorders, such as myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)


You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration